Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14426349 | 0.90 | GPR119 (0.51) | GPR119KDM4EPKMKMT2A | |
| SCHEMBL387056 | 0.87 | GPR119 (0.49) | GPR119KDM4EPKMALOX5APFEN1 | |
| SCHEMBL21606867 | 0.85 | LIPE (0.62) | GPR119KDM4EPKMALOX5APFEN1 | |
| SCHEMBL29913011 | 0.85 | LIPE (0.62) | GPR119KDM4EPKMALOX5APFEN1 | |
| SCHEMBL3098995 | 0.84 | GPR119 (0.63) | GPR119KMT2A | |
| SCHEMBL13993542 | 0.83 | GPR119 (0.67) | GPR119KMT2A | |
| SCHEMBL12834985 | 0.83 | GPR119 (0.58) | GPR119GRIN2BKDM4EPKMKMT2A | |
| SCHEMBL14190957 | 0.82 | GPR119 (0.56) | GPR119 | |
| SCHEMBL1103822 | 0.81 | GPR119 (0.49) | GPR119KDM4EPKMALOX5APFEN1 | |
| SCHEMBL16777142 | 0.81 | GPR119 (0.49) | GPR119KDM4EPKMALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | GPR119 139/4885GRIN2B 40/4885KDM4E 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.